IRIS Institutional Research Information System - OPENBS Open Archive UniBS

TORTI, Carlo
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 13.231
AS - Asia 5.880
EU - Europa 4.484
SA - Sud America 1.189
Continente sconosciuto - Info sul continente non disponibili 167
AF - Africa 131
OC - Oceania 22
Totale 25.104
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 13.051
CN - Cina 2.101
SG - Singapore 1.924
UA - Ucraina 1.422
BR - Brasile 990
DE - Germania 820
HK - Hong Kong 742
IT - Italia 491
FI - Finlandia 426
VN - Vietnam 352
FR - Francia 308
GB - Regno Unito 308
RU - Federazione Russa 242
IE - Irlanda 225
TR - Turchia 213
IN - India 189
BD - Bangladesh 95
CA - Canada 92
AR - Argentina 70
MX - Messico 47
IQ - Iraq 46
EC - Ecuador 44
SE - Svezia 40
NG - Nigeria 35
ZA - Sudafrica 32
NL - Olanda 31
BE - Belgio 28
PK - Pakistan 27
JP - Giappone 24
PL - Polonia 24
AT - Austria 23
ID - Indonesia 21
AU - Australia 20
SA - Arabia Saudita 19
VE - Venezuela 18
ES - Italia 17
UZ - Uzbekistan 17
IR - Iran 16
CZ - Repubblica Ceca 15
KE - Kenya 14
MA - Marocco 14
CO - Colombia 13
LT - Lituania 13
PY - Paraguay 13
CL - Cile 12
UY - Uruguay 12
AZ - Azerbaigian 10
EG - Egitto 10
TN - Tunisia 10
EU - Europa 9
IL - Israele 9
JO - Giordania 9
BO - Bolivia 8
HN - Honduras 8
AE - Emirati Arabi Uniti 7
MY - Malesia 7
PT - Portogallo 7
JM - Giamaica 6
KZ - Kazakistan 6
NP - Nepal 6
PE - Perù 6
DO - Repubblica Dominicana 5
DZ - Algeria 5
OM - Oman 5
PH - Filippine 5
TT - Trinidad e Tobago 5
BB - Barbados 4
HU - Ungheria 4
KG - Kirghizistan 4
MU - Mauritius 4
RO - Romania 4
RS - Serbia 4
SK - Slovacchia (Repubblica Slovacca) 4
BG - Bulgaria 3
BH - Bahrain 3
BY - Bielorussia 3
CH - Svizzera 3
GR - Grecia 3
KH - Cambogia 3
LV - Lettonia 3
MD - Moldavia 3
PA - Panama 3
AL - Albania 2
AM - Armenia 2
CY - Cipro 2
GE - Georgia 2
GY - Guiana 2
HR - Croazia 2
KR - Corea 2
LB - Libano 2
MN - Mongolia 2
MS - Montserrat 2
NI - Nicaragua 2
NZ - Nuova Zelanda 2
SI - Slovenia 2
SN - Senegal 2
BA - Bosnia-Erzegovina 1
CI - Costa d'Avorio 1
CR - Costa Rica 1
ET - Etiopia 1
Totale 24.926
Salva come PNG Salva come JPEG
Città #
Woodbridge 1.411
Fairfield 1.409
Ashburn 1.062
Singapore 1.036
Jacksonville 1.033
Houston 883
Hong Kong 740
Ann Arbor 704
Cambridge 615
Seattle 613
Wilmington 569
San Jose 525
The Dalles 454
Chandler 431
Princeton 411
Nanjing 393
Beijing 355
Dublin 224
Helsinki 198
Columbus 194
Lauterbourg 187
New York 181
Istanbul 174
Los Angeles 171
Nanchang 147
Ho Chi Minh City 138
Moscow 107
Des Moines 105
San Diego 97
Hebei 92
Shenyang 90
Buffalo 86
Changsha 86
São Paulo 81
Jinan 67
Lancaster 66
Tianjin 65
Milan 63
San Francisco 63
Hanoi 61
Shanghai 60
Jiaxing 58
Munich 58
Dallas 53
Redondo Beach 52
Dearborn 51
Chicago 39
Kunming 39
Hangzhou 38
Abuja 35
Verona 35
Brescia 34
Orem 34
Toronto 33
Santa Clara 31
Frankfurt am Main 30
London 30
Rio de Janeiro 29
Council Bluffs 28
Brussels 27
Belo Horizonte 26
Montreal 24
Tokyo 22
Turku 21
Nuremberg 20
Warsaw 20
Washington 20
Brooklyn 19
Ningbo 19
Zhengzhou 19
Campinas 18
Guangzhou 18
Johannesburg 18
Porto Alegre 18
Atlanta 17
Boardman 17
Brasília 17
Lanzhou 17
Quito 17
Tashkent 17
Ardabil 16
Curitiba 16
Chennai 15
Mexico City 15
Amsterdam 14
Changchun 14
Da Nang 14
Dhaka 14
Kocaeli 13
Mumbai 13
Nairobi 13
Rome 13
Denver 12
Haiphong 12
Manchester 12
Norwalk 12
Phoenix 12
Ribeirão Preto 12
Salvador 12
Buenos Aires 11
Totale 16.830
Salva come PNG Salva come JPEG
Nome #
Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study. 296
The Disagreement Among Methods to Evaluate Glomerular Filtration Rate in HIV-Infected Patients Naive to Antiretroviral Therapy. 234
The evolving burden of HIV infection compared with other chronic diseases in northern Italy 214
Evolution of transmitted HIV-1 drug resistance in HIV-1-infected patients in Italy from 2000 to 2010. 204
Evaluation of Liver Fibrosis: Concordance Analysis between Noninvasive Scores (APRI and FIB-4) Evolution and Predictors in a Cohort of HIV-Infected Patients without Hepatitis C and B Infection 198
Efficacy and safety of a switch to unboosted atazanavir in combination with nucleoside analogues in HIV-1-infected patients with virological suppression under antiretroviral therapy 185
HIV-associated asymmetric lipodystrophy syndrome 184
Contribution of Genetic Background, Traditional Risk Factors, and HIV-Related Factors to Coronary Artery Disease Events in HIV-Positive Persons 184
Risk of Liver Enzyme Elevation During Treatment With Ritonavir-Boosted Protease Inhibitors Among HIV-Monoinfected and HIV/HCV-Coinfected Patients 182
Virological effectiveness and CD4+ T-cell increase over early andlate courses in HIV infected patients on antiretroviral therapy: focus on HCV andanchor class received 181
Influence of folate serum concentration on plasma homocysteine levels in HIV-positive patients exposed to protease inhibitors undergoing HAART. 180
No evidence of relation between peripheral neuropathy and presence of hemochromatosis gene mutations in HIV-1-positive patients. 180
Adherence and plasma drug concentrations are predictors of confirmed virologic response after 24-week salvage highly active antiretroviral therapy. 178
Analysis of HIV-1 mutation patterns in patients failing antiretroviral therapy 178
Dideoxynucleoside HIV reverse transcriptase inhibitors and drug-related hepatotoxicity: a case report. 176
Changes over time in risk factors for cardiovascular disease and use of lipid-lowering drugs in HIV-infected individuals and impact on myocardial infarction 173
Modifications of health resource-use in Italy after the introduction of highly active antiretroviral therapy (HAART) for human immunodeficiency virus (HIV) infection. Pharmaco-economic implications in a population-based setting 171
Use of efavirenz or atazanavir/ritonavir is associated with better clinical outcomes of HAART compared to other protease inhibitors: Routine evidence from the Italian MASTER Cohort 171
Genotype resistance profiles in patients failing an NNRTI-containing regimen, and modifications after stopping NNRTI therapy 169
Heterogeneity and penetration of HIV-1 non-subtype B viruses in an Italian province: public health implications. 167
Bcl-2 expression is moderately correlated with long-term variability of CD4+ T-cell increase under successful highly active antiretroviral therapy 165
Prediction of early and confirmed virological response by genotypic inhibitory quotients for lopinavir in patients naive for lopinavir with limited exposure to previous protease inhibitors. 165
Influence of viral chronic hepatitis co-infection on plasma drug concentrations and liver transaminase elevations upon therapy switch in HIV-positive patients. 164
Effectiveness of antiretroviral regimens containing abacavir with tenofovir in treatment-experienced patients: predictors of virological response and drug resistance evolution in a multi-cohort study. 164
Risk of chronic kidney disease among patients developing mild renal impairment during tenofovir-containing antiretroviral treatment 163
Effects of combined antiretroviral therapy on B- and T-cell release from production sites in long-term treated HIV-1+ patients 163
Key Questions in antiretroviral therapy: Italian Consensus Workshop (2005) 160
Successful long-course after failure of short-course desensitization in a patient with severe hypersensitivity reaction to enfuvirtide 160
HIV-1 genotype resistance pattern and evolution in patients failing nelfinavir containing regimens 157
Hepatitis C virus antibody-positive patients with HIV infection have a high risk of insulin resistance: a cross-sectional study 157
Incidence and risk factors for liver enzyme elevation during highly active antiretroviral therapy in HIV-HCV co-infected patients: results from the Italian EPOKA-MASTER Cohort. 156
All-cause mortality in treated HIV-infected adults with CD4 >=500/mm3 compared with the general population: evidence from a large European observational cohort collaboration  156
HIV susceptibility to amprenavir: phenotype-based versus rules-based interpretations 155
Long-term CD4+ T-cell count evolution after switching from regimens including HIV nucleoside reverse transcriptase inhibitors (NRTI) plus protease inhibitors to regimens containing NRTI plus non-NRTI or only NRTI 154
Modifications in SENV DNA detection and/or SENV subtype determination over a prospective follow-up in a cohort of HIV-positive patients: is this a moving target? 153
Factors influencing the normalization of CD4+ T-cell count, percentage and CD4+/CD8+ T-cell ratio in HIV-infected patients on long-term suppressive antiretroviral therapy. 152
Observational Study on HIV-Infected Subjects Failing HAART Receiving Tenofovir Plus Didanosine as NRTI Backbone. 151
Calendar time trends in the incidence and prevalence of triple-class virologic failure in antiretroviral drug-experienced people with HIV in Europe. 151
Analisi estensiva di sequenza dei geni della trascrittasi inversa e della proteasi di HIV-1 in una coorte clinica di pazienti HIV positivi NAIVE per la terapia antiretrovirale. 150
Impact of detectable human cytomegalovirus DNAemia on viro-immunologicaleffectiveness of HAART in HIV-infected patients naive to antiretroviral therapy 149
A comparison of three computational modelling methods for the prediction of virological response to combination HIV therapy 148
Drug resistance mutations and newly recognized treatment-related substitutions in the HIV-1 protease gene: prevalence and associations with drug exposure and real or virtual phenotypic resistance to protease inhibitors in two clinical cohorts of antiretroviral experienced patients. 147
HIV-induced immunodeficiency and mortality from AIDS-defining and non-AIDS-defining malignancies 146
CD4+ T cell evolution and predictors of its trend before and aftertenofovir/didanosine backbone in the presence of sustained undetectable HIV plasma viral load 145
HIV-1 resistance to dideoxynucleoside reverse transcriptase inhibitors: genotypic-phenotypic correlations 145
Specific prebiotics modulate gut microbiota and immune activation in HAART-naive HIV-infected adults: results of the “COPA” pilot randomized trial 144
Comparison of HIV-1 genotypic resistance test interpretation systems in predicting virological outcomes over time. 143
The development of an expert system to predict virological response to HIV therapy as part of an online treatment support tool 140
Immune correlates of virological response in HIV-positive patients after highly active antiretroviral therapy (HAART) 139
Towards HCV extinction with modern HCV treatment? “Yes we can!” 138
Maternal characteristics during pregnancy and risk factors for positive HIV RNA at delivery: a single-cohort observational study (Brescia, Northern Italy). 137
Potential role of SEN virus on liver enzyme abnormalities in patients positive for hepatitis C virus with or without HIV infection. 136
Impact of unreported HIV-1 reverse transcriptase mutations on phenotypic resistance to nucleoside and non-nucleoside inhibitors. 136
Real versus virtual phenotype to guide treatment in heavily pretreated patients: 48 week follow-up of the Genotipo-Fenotipo di Resistenza (GenPheRex) trial 136
Recent acquired STD and the use of HAART in the Italian Cohort of Naive for Antiretrovirals (I.Co.N.A): analysis of the incidence of newly acquired hepatitis B infection and syphilis 136
Detection of drug resistance mutations at low plasma HIV-1 RNA load in a European multicentre cohort study 136
Diagnosi sierologica di infezioni da HIV 2: confronto tra Western Blot NEW LAW Blot II e PEPTI-LAV 1-2 135
Polymorphic immune restoration syndrome after effective HAART 134
Risk of triple-class virological failure in children with HIV: a retrospective cohort study 134
A king in the CASTLE? Optimum initial HIV protease inhibitor. 133
Therapeutic immunization with HIV-1 Tat reduces immune activation and loss of regulatory T-cells and improves immune function in subjects on HAART 133
Clinical Evaluation of Rega 8: An Updated Genotypic Interpretation System That Significantly Predicts HIV-Therapy Response 133
Hyperbilirubinemia during atazanavir treatment in 2,404 patients in the Italian atazanavir expanded access program and MASTER Cohorts 133
Adherence and plasma drug concentrations are predictors of confirmed virologic response after 24-week salvage highly active antiretroviral therapy 133
Comparison of a rule-based algorithm with a phenotype-based algorithm for the interpretation of HIV genotypes in guiding salvage regimens in HIV-infected patients by a randomized clinical trial: the mutations and salvage study. 132
Risk factors for myocardial infarction in HIV positive patients 132
Mortality from HIV and TB coinfections is higher in Eastern Europe than in Western Europe and Argentina 132
I data-base clinici e la sorveglianza degli eventi avversi: il progetto MASTER 131
Analysis of severe hepatic events associated with nevirapine-containing regimens: CD4+ T-cell count and gender in hepatitis C seropositive and seronegative patients. 131
Plasma HIV load and proviral DNA decreases after two standard antiretroviral regimens in HIV-positive patients naïve to antiretrovirals 131
The convenience of flow cytometry for HLA-B*5701 screening to prevent abacavir hypersensitivity reactions 131
HIV/HTLV co-infection: frequency and epidemiological characteristics among patients admitted to an Italian hospital 129
Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study 129
Natural history of chronic hepatitis B in co-infected patients. 128
Long-term immunological benefit in patients with discordant responses to therapy depends on both level of viremia and duration of rebound 128
Two different patterns of mutations are involved in the genotypic resistance score for atazanavir boosted versus unboosted by ritonavir in multiple failing patients 128
Antiretroviral genotyping resistance in plasma RNA and whole blood DNA in HIV-1 infected patients failing HAART 127
Variable impact on mortality of AIDS-defining events diagnosed during combination antiretroviral therapy: not all AIDS-defining conditions are created equal 127
Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration 127
Incidence and risk factors of HIV-related non-Hodgkin's lymphoma in the era of combination antiretroviral therapy: a European multicohort study 127
Nucleoside analogue use before and during highly active antiretroviral therapy and virus load rebound. 126
Microbial translocation predicts disease progression of HIV-infected antiretroviral-naive patients with high CD4+ cell count 126
Viral tropism by geno2pheno as a tool for predicting CD4 decrease in HIV-1-infected naive patients with high CD4 counts 126
First Italian Consensus Statement on Diagnosis, Prevention and Treatment of Cardiovascular Complications in HIV-infected Patients in the HAART Era (2006). 125
A randomized, controlled trial of triple antiviral therapy as initial treatment of chronic hepatitis C in HIV-infected patients 125
Prevalence of hypovitaminosis D and factors associated with vitamin D deficiency and morbidity among HIV-infected patients enrolled in a large Italian cohort 125
Declining prevalence of HIV-1 drug resistance in antiretroviral treatment-exposed individuals in Western Europe. 125
Genetic polymorphisms differently influencing the emergence of atrophy and fataccumulation in HIV-related lipodystrophy 125
Predictors of CD4+ T-Cell Counts of HIV Type 1-Infected Persons After Virologic Failure of All 3 Original Antiretroviral Drug Classes 125
The use of ultrasonography, transient elestography, APRI and FIB-4 to measure liver steatosis and fibrosis in HIV-positive patients not co-infected with hepatitis viruses with hypertransaminasemia of unknown origin on HAART 124
A comparison between abacavir and efavirenz as the third drug used in combination with a background therapy regimen of 2 nucleoside reverse-transcriptase inhibitors in patients with initially suppressed viral loads 124
Risk of developing specific AIDS-defining illnesses in patients coinfected with HIV and hepatitis C virus with or without liver cirrhosis 123
Lipid abnormalities in HIV-infected patients are not correlated with lopinavir plasma concentrations. 123
Co-infezione HIV-HCV e dislipidemie in corso di Highly Active Antiretroviral Therapy (HAART) 123
"Solving the puzzle" of current HAART: what key strategic trials are needed? 122
Influence of hepatitis C genotypes on lipid levels in HIV-positive patients during highly active antiretroviral therapy. 121
Pharmacokinetics of efavirenz (EFV) alone and in combination therapy with nelfinavir (NFV) in HIV-1 infected patients. 120
Role of serum free light chains in predicting HIV-associated non-Hodgkin lymphoma and Hodgkin's lymphoma and its correlation with antiretroviral therapy. 120
The Impact of Gender and Anchor Drugs on TDF Renal Toxicity 120
Triple-class virologic failure in HIV-infected patients undergoing antiretroviral therapy for up to 10 years 119
Totale 14.807
Salva come PNG Salva come JPEG
Categoria #
all - tutte 114.910
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 114.910
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.477 76 275 7 89 5 87 61 98 69 195 141 374
2022/20231.374 225 18 11 83 131 416 0 129 228 15 44 74
2023/20241.164 74 24 67 114 46 172 35 32 372 14 15 199
2024/20253.076 28 10 12 339 440 247 319 101 290 263 637 390
2025/20265.970 576 854 398 880 632 368 1.017 212 345 431 167 90
2026/2027302 302 0 0 0 0 0 0 0 0 0 0 0
Totale 25.104